Otsuji E, Yamaguchi T, Yamaoka N, Kitamura K, Yamaguchi N, Takahashi T
First Department of Surgery, Kyoto Prefectural University of Medicine, Japan.
J Surg Oncol. 1993 Aug;53(4):215-9. doi: 10.1002/jso.2930530405.
We investigated the following in athymic nude mice with xenografts of a human pancreatic carcinoma: 1) clearance of the murine monoclonal antibody A7 from the carcinoma; and 2) the antitumor effect of neocarzinostatin conjugated to MAb A7 (A7-NCS) on the carcinoma following intratumoral injection. Compared with 125I-labeled normal mouse IgG, a significantly larger amount of 125I-labeled A7 remained in the tumor after intratumoral injection. Neocarzinostatin conjugated to MAb A7 showed a greater antitumor activity against human pancreatic cancer than neocarzinostatin alone after intratumoral administration. The conjugate completely suppressed tumor growth macroscopically during the experiment. Tumor tissue in mice became necrotic 32 days after injection with A7-NCS. These observations suggest that the intratumoral injection of A7-NCS offers promise in treating pancreatic carcinoma.
1）鼠单克隆抗体A7从癌组织中的清除情况；2）瘤内注射与单克隆抗体A7偶联的新制癌菌素（A7-NCS）对癌组织的抗肿瘤作用。与125I标记的正常小鼠IgG相比，瘤内注射后肿瘤中残留的125I标记的A7量明显更多。瘤内给药后，与单克隆抗体A7偶联的新制癌菌素对人胰腺癌显示出比单独使用新制癌菌素更强的抗肿瘤活性。在实验过程中，该偶联物在宏观上完全抑制了肿瘤生长。注射A7-NCS后32天，小鼠的肿瘤组织发生坏死。这些观察结果表明，瘤内注射A7-NCS在治疗胰腺癌方面具有前景。
